Document Detail


Relationship of technetium-99m tetrofosmin-gated rest single-photon emission computed tomography myocardial perfusion imaging to death and hospitalization in heart failure patients: results from the nuclear ancillary study of the HF-ACTION trial.
MedLine Citation:
PMID:  21641348     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: We hypothesized that the severity of resting perfusion abnormalities assessed by the summed rest score (SRS) would be associated with a higher rate of adverse outcomes in patients with heart failure (HF) and reduced left ventricular (LV) ejection fraction (EF).
METHODS: A subset of 240 subjects from HF-ACTION underwent resting technetium-99m tetrofosmin-gated single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). Images were evaluated using a 17-segment model to derive the SRS and additional nuclear variables.
RESULTS: After adjusting for prespecified covariates, SRS was significantly associated with the primary end point (hazard ratio 0.98, 95% confidence interval [CI] 0.97-1.00, P = .04), with a higher SRS corresponding to lower risk of an event. This association was not present in the unadjusted analysis. The relationship between SRS and the primary outcome was likely due to a higher event ratein patients with ischemic HF and a low SRS. The LV phase SD was not predictive of the primary outcome (hazard ratio 1.00, 95% confidence interval 0.99-1.01, P = .49). In a post hoc analysis, nuclear variables provided incremental prognostic information when added to clinical information (P = .006).
CONCLUSIONS: Gated SPECT MPI provides important information in patients with HF and reduced LVEF. In the adjusted analysis, SRS has an unexpected relationship with the primary end point. Phase SD was not associated with the primary end point. Rest-gated SPECT MPI provides incrementally greater prognostic information than clinical information alone.
Authors:
Allen E Atchley; Ami E Iskandrian; Dan Bensimhon; Stephen J Ellis; Dalane W Kitzman; Linda K Shaw; Robert A Pagnanelli; David J Whellan; Julius M Gardin; Andrew Kao; Khaled Abdul-Nour; Greg Ewald; Mary Norine Walsh; William E Kraus; Christopher M O'Connor; Salvador Borges-Neto;
Related Documents :
3744768 - Epidemiologic methodology in evaluating health technology.
6469268 - Monoclonal antibody to cardiac myosin: imaging of experimental myocardial infarction.
19451998 - Myocardial tissue characterization based on the time-resolved stokes-mueller formalism.
25267078 - A call to arms: new approaches to an old heart failure problem.
6686528 - Apical hypertrophic cardiomyopathy: clinical and metabolic studies.
10678448 - Left ventricular volume reduction for end-stage heart disease.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial     Date:  2011-04-06
Journal Detail:
Title:  American heart journal     Volume:  161     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-06-06     Completed Date:  2011-08-23     Revised Date:  2013-08-19    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1038-45     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2011 Mosby, Inc. All rights reserved.
Affiliation:
Duke University Medical Center, Durham, NC 27710, USA.
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00047437
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Female
Heart Failure / drug therapy,  mortality,  physiopathology*,  radionuclide imaging*
Humans
Male
Middle Aged
Organophosphorus Compounds / diagnostic use*
Organotechnetium Compounds / diagnostic use*
Prognosis
Radiopharmaceuticals / diagnostic use*
Stroke Volume
Tomography, Emission-Computed, Single-Photon*
Ventricular Dysfunction, Left / radionuclide imaging
Grant Support
ID/Acronym/Agency:
R37 AG018915/AG/NIA NIH HHS; U01 HL063747/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Organophosphorus Compounds; 0/Organotechnetium Compounds; 0/Radiopharmaceuticals; 0/technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prognostic value of cardiac troponin T in patients with moderate to severe heart failure scheduled f...
Next Document:  Time course of restoration of systolic and diastolic right ventricular function after pulmonary enda...